Literature DB >> 16078322

Immune status and risk for infection in patients receiving chronic immunosuppressive therapy.

Thomas Glück1, Bernhard Kiefmann, Mathias Grohmann, Werner Falk, Rainer H Straub, Jürgen Schölmerich.   

Abstract

OBJECTIVE: Chronic immunosuppressive therapy may be complicated by infections indicating a more or less profound immune defect. However, immune monitoring to estimate the risk for infection has so far not been performed routinely. The aim of this study was (1) to investigate the effects of commonly used immunosuppressive treatment regimens on lymphocyte subsets and cytokine release from stimulated whole blood cultures in patients with rheumatic or autoimmune diseases; and (2) to determine whether such measurements could be used as predictors of infection, and if so, to determine their predictive value for subsequent infectious complications.
METHODS: Patients with various chronic inflammatory diseases (n = 97) treated with different immunosuppressive regimens and healthy controls (n = 36) were evaluated for T lymphocyte subsets and for cytokine release in whole blood cultures after stimulation with lipopolysaccharide (LPS) or phorbol myristate acetate (PMA) and ionomycin.
RESULTS: Therapy with corticosteroids induced dose-dependent lymphocyte depletion. Concomitant application of cytotoxic disease modifying drugs and corticosteroids caused an additive effect on lymphocytopenia, but did not change CD4/CD8 ratio. Corticosteroid therapy was also associated with impaired cytokine release from mononuclear cells in whole blood assays after in vitro stimulation with LPS or PMA/ionomycin. Infections requiring hospitalization developed in 19 of 95 evaluable patients during an average followup period of 2.3 years. On logistic regression analysis, lymphocytopenia < 600/microl, in particular < 250 CD4+ T cells/microl, and therapy with corticosteroids > 10 mg prednisolone equivalent per day were predictive of infections. Multiple logistic regression analysis showed that T-helper lymphocytopenia < 250/microl was the best predictor for future infections, with a positive predictive value of 0.53 and a negative predictive value of 0.97.
CONCLUSION: Patients receiving chronic immunosuppressive therapy can develop severe lymphopenia that involves all subsets. Monitoring T-helper cell counts may be useful to estimate the risk for subsequent infections in such patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16078322

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  36 in total

Review 1.  [Infections as causes of fever of unknown origin].

Authors:  A Schneidewind; B Ehrenstein; B Salzberger
Journal:  Internist (Berl)       Date:  2009-06       Impact factor: 0.743

2.  Rituximab off-label use for immune diseases: assessing adverse events in a single-centre drug-utilization survey.

Authors:  Laurent Sailler; Camille Attane; Fleur Michenot; Jean-Marie Canonge; Lionel Rostaing; Elizabeth Arlet-Suau; Philippe Arlet; François Launay; Jean-Louis Montastruc; Maryse Lapeyre-Mestre
Journal:  Br J Clin Pharmacol       Date:  2008-04-10       Impact factor: 4.335

3.  [Rare viral infections during immunosuppressive therapy: a "normal" side effect?].

Authors:  T Glück
Journal:  Z Rheumatol       Date:  2011-07       Impact factor: 1.372

4.  Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression.

Authors:  Thomas G Cotter; Nicola Gathaiya; Jelena Catania; Edward V Loftus; William J Tremaine; Larry M Baddour; W Scott Harmsen; Alan R Zinsmeister; William J Sandborn; Andrew H Limper; Darrell S Pardi
Journal:  Clin Gastroenterol Hepatol       Date:  2016-12-21       Impact factor: 11.382

5.  Antifungal therapy in a murine model of disseminated infection by Cryptococcus gattii.

Authors:  Enrique Calvo; F Javier Pastor; M Mar Rodríguez; Isabel Pujol; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

6.  [Fever of unknown origin. Infectious causes].

Authors:  B Salzberger; A Schneidewind; F Hanses; G Birkenfeld; M Müller-Schilling
Journal:  Internist (Berl)       Date:  2012-12       Impact factor: 0.743

Review 7.  Vaccine-preventable infections in Systemic Lupus Erythematosus.

Authors:  Giuseppe Murdaca; Andrea Orsi; Francesca Spanò; Valeria Faccio; Francesco Puppo; Paolo Durando; Giancarlo Icardi; Filippo Ansaldi
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

8.  Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis.

Authors:  Rémi Goupil; Soumeya Brachemi; Annie-Claire Nadeau-Fredette; Clément Déziel; Yves Troyanov; Valery Lavergne; Stéphan Troyanov
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-06       Impact factor: 8.237

9.  Idiopathic CD4 lymphocytopenia presenting as refractory cryptococcal meningitis.

Authors:  A Sharma; V Lal; M Modi; D Khurana; S Bal; S Prabhakar
Journal:  Ann Indian Acad Neurol       Date:  2010-04       Impact factor: 1.383

10.  Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis.

Authors:  Marko Lucijanic; Ivo Veletic; Dario Rahelic; Vlatko Pejsa; David Cicic; Marko Skelin; Ana Livun; Katarina Marija Tupek; Tajana Stoos-Veic; Tomo Lucijanic; Ana Maglicic; Rajko Kusec
Journal:  Wien Klin Wochenschr       Date:  2018-01-25       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.